In partnership with
Letter from the Editor
Vericiguat shows beneficial effects in a very high-risk HF population
Mavacamten shows promising results in non-obstructive hypertrophic cardiomyopathy
No role for sodium nitrite in out-of-hospital cardiac arrest
Rivaroxaban and aspirin effective and safe for PAD patients
Subgroup analysis VOYAGER PAD
TAILOR-PCI misses endpoint but still provides valuable insights
Edoxaban: alternative to warfarin after surgical aortic or mitral valve procedures?
Bleeding reduction post-TAVI with OAC alone vs OAC + clopidogrel
Apixaban offers new perspective for cancer patients in need of anticoagulation
Rivaroxaban superior to enoxaparin in preventing VTE in non-major orthopaedic surgery
TAVR safe and effective in low-risk bicuspid aortic stenosis patients
TAVR model reveals differences in hospital outcomes
TAVR versus surgery in older patients
Real-world evidence for MitraClip
2-year results show non-significant outcomes TAVR vs surgery in severe aortic stenosis
Renal denervation better than sham for blood pressure
Radial artery best for second bypass
PCI and CABG are equal in left main CAD
Infusion of ethanol in the vein of Marshall for persistent AF
Fewer adverse events with ticagrelor monotherapy after 3 months DAPT
TWILIGHT sub-study: same outcomes for diabetes patients
TWILIGHT sub-study: complex PCI patients
LAAO Watchman registry data positive
Apixaban in AF patients with recent ACS/PCI: Drop aspirin after 30 days
Homozygous FH responds to alirocumab
Evinacumab significantly reduces LDL-C in homozygous FH patients
Higher serum levels of eicosapentaenoic acid correlate with reduced CV events
Quit smoking: vaping + counselling helps
Top image: @ iStockPhoto: MStudioImages
The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.
BACK TO TOP